Targeted Antibody-Drug could shrink Hard-to-Treat ovarian cancers
NCT ID NCT07674615
First seen Jun 29, 2026 · Last updated Jul 01, 2026 · Updated 2 times
Summary
This trial tests a drug called sacituzumab govitecan in people with advanced or recurrent ovarian, fallopian tube, or primary peritoneal cancer that has high levels of a protein called TROP-2. Participants must have already tried standard treatments without success. The drug is given by IV on days 1 and 8 of each 21-day cycle. The main goal is to see how many patients have their tumors shrink or disappear.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sacituzumab govitecan
What this could lead to
If effective, this could offer a new treatment option for people with advanced ovarian cancer that has stopped responding to standard therapies.
What could go wrong
This is an early-phase trial with only 19 participants, so results may not apply broadly. The drug may cause side effects or fail to shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital Fudan University
Shanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••